|
GB1062357A
(en)
*
|
1965-03-23 |
1967-03-22 |
Pfizer & Co C |
Quinazolone derivatives
|
|
US4337341A
(en)
*
|
1976-11-02 |
1982-06-29 |
Eli Lilly And Company |
4a-Aryl-octahydro-1H-2-pyrindines
|
|
DE3815221C2
(de)
|
1988-05-04 |
1995-06-29 |
Gradinger F Hermes Pharma |
Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
|
|
US5698155A
(en)
|
1991-05-31 |
1997-12-16 |
Gs Technologies, Inc. |
Method for the manufacture of pharmaceutical cellulose capsules
|
|
RU2065438C1
(ru)
|
1993-12-22 |
1996-08-20 |
Институт химии природного органического сырья СО РАН |
Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она
|
|
US6635626B1
(en)
|
1997-08-25 |
2003-10-21 |
Bristol-Myers Squibb Co. |
Imidazoquinoxaline protein tyrosine kinase inhibitors
|
|
US5998463A
(en)
|
1998-02-27 |
1999-12-07 |
Pfizer Inc |
Glycogen phosphorylase inhibitors
|
|
US6476032B2
(en)
|
1998-12-17 |
2002-11-05 |
Wyeth |
2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives
|
|
JP2003501429A
(ja)
|
1999-06-03 |
2003-01-14 |
クノール・ゲー・エム・ベー・ハー |
ベンゾチアジノンおよびベンゾオキサジノン化合物
|
|
FR2807660A1
(fr)
|
2000-04-13 |
2001-10-19 |
Warner Lambert Co |
Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
|
|
ATE343575T1
(de)
|
2001-09-27 |
2006-11-15 |
Smithkline Beecham Corp |
Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
|
|
KR20030095729A
(ko)
|
2002-06-14 |
2003-12-24 |
크리스탈지노믹스(주) |
2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5Ｈ-티아졸로[3,2-ａ]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1Ｂ 활성 억제용 약학 조성물
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
ZA200502612B
(en)
|
2002-10-08 |
2007-07-25 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
|
|
IL154370A0
(en)
*
|
2003-02-10 |
2003-09-17 |
Chemagis Ltd |
Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
|
|
ES2320771T3
(es)
|
2003-04-16 |
2009-05-28 |
Bristol-Myers Squibb Company |
Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
|
|
EP1663962A4
(en)
|
2003-08-22 |
2007-08-22 |
Dendreon Corp |
COMPOSITIONS AND METHODS FOR TREATING A DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION
|
|
WO2008021463A2
(en)
|
2006-08-15 |
2008-02-21 |
Acadia Pharmaceuticals, Inc. |
Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
|
|
JP5301152B2
(ja)
|
2004-04-07 |
2013-09-25 |
ライナット ニューロサイエンス コーポレイション |
神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
|
|
WO2006007864A1
(en)
|
2004-07-17 |
2006-01-26 |
Max Planck Geselllschaft Zur Förderung Der Wissenschaft |
Treating neurodegenerative conditions
|
|
US7671077B2
(en)
*
|
2004-07-19 |
2010-03-02 |
Leu-Fen Hou Lin |
Neuroprotective small organic molecules, compositions and uses related thereto
|
|
WO2006036936A2
(en)
|
2004-09-27 |
2006-04-06 |
Bridge Pharma, Inc. |
The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
|
|
WO2006078711A2
(en)
|
2005-01-19 |
2006-07-27 |
Mgi Gp, Inc. |
Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
|
|
FR2881138B1
(fr)
|
2005-01-27 |
2007-03-02 |
Servier Lab |
Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US20060257337A1
(en)
|
2005-04-28 |
2006-11-16 |
David Sherris |
Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
|
|
JP5191155B2
(ja)
|
2006-03-27 |
2013-04-24 |
大塚製薬株式会社 |
カルボスチリル化合物からなる医薬
|
|
JP2007303392A
(ja)
|
2006-05-11 |
2007-11-22 |
Honda Motor Co Ltd |
気体燃料内燃機関の制御装置
|
|
WO2008053863A1
(en)
|
2006-10-30 |
2008-05-08 |
Santen Pharmaceutical Co., Ltd. |
Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
|
|
CN101616919B
(zh)
|
2006-12-28 |
2012-10-10 |
雅培制药有限公司 |
聚（adp核糖）聚合酶抑制剂
|
|
WO2009024989A2
(en)
|
2007-08-17 |
2009-02-26 |
Hetero Drugs Limited |
A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
|
|
EP2227859B1
(en)
|
2007-11-16 |
2017-11-01 |
Gula Consulting Limited Liability Company |
Filter design methods and filters based on metamaterial structures
|
|
CA2746220A1
(en)
|
2008-12-08 |
2010-07-08 |
Vm Pharma Llc |
Compositions of protein receptor tyrosine kinase inhibitors
|
|
EP2239256A1
(en)
*
|
2009-03-13 |
2010-10-13 |
Almirall, S.A. |
Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
|
|
WO2011063398A1
(en)
*
|
2009-11-23 |
2011-05-26 |
Cylene Pharamaceuticals, Inc. |
Polymorphs and salts of a kinase inhibitor
|
|
CN102947308A
(zh)
|
2010-06-23 |
2013-02-27 |
Osi药物有限责任公司 |
Osi-906的多晶型物
|
|
TWI674262B
(zh)
|
2011-01-10 |
2019-10-11 |
美商英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
|
WO2012119079A1
(en)
|
2011-03-03 |
2012-09-07 |
Indiana University Research And Technology Corporation |
uPAR-uPA INTERACTION INHIBITORS AND METHODS FOR TREATING CANCER
|
|
US8999992B2
(en)
|
2013-03-15 |
2015-04-07 |
Vm Pharma Llc |
Crystalline forms of tryosine kinase inhibitors and their salts
|
|
US10301271B2
(en)
|
2014-09-17 |
2019-05-28 |
Purdue Pharma L.P. |
Crystalline forms of tyrosine kinase inhibitors and their salts
|